Incyte Announces 24-Week Long-Term Data from Phase 3 TRuE-AD4 Trial of Opzelura® (ruxolitinib) Cream in Adults with Moderate Atopic Dermatitis
Thursday, May 7, 2026 1 min read
Key Takeaway: Incyte has released final 24-week data from the Phase 3 TRuE-AD4 trial, which assessed the efficacy and safety of Opzelura (ruxolitinib) cream in adults suffering from moderate atopic dermatitis. The study focused on patients who had inadequate responses to traditional treatments like topical corticosteroids and calcineurin inhibitors. The findings were presented at the 2026 EADV conference.
Market Sentiment Analysis
POSITIVE FACTORS
Final data from Phase 3 study shows efficacy of Opzelura.
Study targets adults with moderate atopic dermatitis.
Presented data at a significant dermatology conference.
Full Press Release Details
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) today announced final 24-week data from the Phase 3 TRuE-AD4 study evaluating the efficacy and safety of Opzelura® (ruxolitinib) cream in adults with moderate atopic dermatitis (AD) who had an inadequate response, intolerance or contraindication to topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs). These data were presented (Abstract ID: P0851) today at the 2026 European Academy of Dermatology and Venereology (EADV)
Frequently Asked Questions
What is Opzelura used for?
Opzelura (ruxolitinib) cream is used to treat moderate atopic dermatitis.
What were the results of the TRuE-AD4 trial?
The trial showed positive efficacy and safety data for Opzelura after 24 weeks.
Where were the trial results presented?
The results were presented at the 2026 European Academy of Dermatology and Venereology.
Who were the participants in the trial?
Participants included adults with moderate atopic dermatitis who did not respond to other treatments.